Daily High to Daily Low: Is It Safe to Buy Oncternal Therapeutics Inc. (ONCT)?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Oncternal Therapeutics Inc. (NASDAQ:ONCT) went up by 8.43% from its latest closing price compared to the recent 1-year high of $9.45. The company’s stock price has collected 16.21% of gains in the last five trading sessions. Press Release reported 13 hours ago that Thinking about buying stock in Hyliion Holdings, BlackBerry, GT Biopharma, Seelos Therapeutics, or Oncternal Therapeutics?

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Oncternal Therapeutics Inc. (NASDAQ :ONCT) Right Now?

Plus, the 36-month beta value for ONCT is at 1.73. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Oncternal Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


The average price from analysts is $15.00. ONCT currently public float of 43.48M and currently shorts hold a 0.49% ratio of that float. Today, the average trading volume of ONCT was 1.56M shares.

ONCT’s Market Performance

ONCT stocks went up by 16.21% for the week, with a monthly jump of 73.89% and a quarterly performance of 93.61%, while its annual performance rate touched 230.63%. The volatility ratio for the week stands at 10.30% while the volatility levels for the past 30 days are set at 11.86% for Oncternal Therapeutics Inc.. The simple moving average for the period of the last 20 days is 18.61% for ONCT stocks with a simple moving average of 131.36% for the last 200 days.

Analysts’ Opinion of ONCT

Many brokerage firms have already submitted their reports for ONCT stocks, with Oppenheimer repeating the rating for ONCT by listing it as a “Outperform.” The predicted price for ONCT in the upcoming period, according to Oppenheimer is $14 based on the research report published on April 07th of the current year 2021.

Northland Capital, on the other hand, stated in their research note that they expect to see ONCT reach a price target of $21. The rating they have provided for ONCT stocks is “Outperform” according to the report published on February 23rd, 2021.

ONCT Trading at 31.86% from the 50-Day Moving Average

After a stumble in the market that brought ONCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.63% of loss for the given period.

Volatility was left at 11.86%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +67.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +71.66% upper at present.

During the last 5 trading sessions, ONCT rose by +16.21%, which changed the moving average for the period of 200-days by +215.10% in comparison to the 20-day moving average, which settled at $8.11. In addition, Oncternal Therapeutics Inc. saw 91.63% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ONCT starting from CARTER MICHAEL G, who purchase 71,429 shares at the price of $2.10 back on Sep 01. After this action, CARTER MICHAEL G now owns 71,947 shares of Oncternal Therapeutics Inc., valued at $150,001 using the latest closing price.

AKER HAZEL M, the Legal Counsel of Oncternal Therapeutics Inc., purchase 41,972 shares at $2.38 during a trade that took place back on Jul 21, which means that AKER HAZEL M is holding 46,987 shares at $99,998 based on the most recent closing price.

Stock Fundamentals for ONCT

Current profitability levels for the company are sitting at:

  • -519.76 for the present operating margin

The net margin for Oncternal Therapeutics Inc. stands at -510.37. The total capital return value is set at -27.52, while invested capital returns managed to touch -27.05. Equity return is now at value -46.40, with -38.50 for asset returns.

Based on Oncternal Therapeutics Inc. (ONCT), the company’s capital structure generated 0.04 points at debt to equity in total, while total debt to capital is 0.04.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of -5.10, with the company’s debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.14.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.